ASCO: Bone Meds, Esophageal Cancers Linked

CHICAGO (MedPage Today) — The esophageal cancer risk with bisphosphonate bone drugs may be a bigger problem than thought, particularly with use of alendronate (Fosamax), an adverse event surveillance study suggested.

Post a Comment

Comments are closed.